Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Effect of influenza H1N1 neuraminidase V116A and I117V mutations on NA activity and sensitivity to NA inhibitors.

Adams SE, Lee N, Lugovtsev VY, Kan A, Donnelly RP, Ilyushina NA.

Antiviral Res. 2019 Sep;169:104539. doi: 10.1016/j.antiviral.2019.104539. Epub 2019 Jun 19.

PMID:
31228489
2.

A comparison of interferon gene expression induced by influenza A virus infection of human airway epithelial cells from two different donors.

Ilyushina NA, Dickensheets H, Donnelly RP.

Virus Res. 2019 Apr 15;264:1-7. doi: 10.1016/j.virusres.2019.02.002. Epub 2019 Feb 16.

PMID:
30779949
3.

Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh.

Lewis KDC, Ortiz JR, Rahman MZ, Levine MZ, Rudenko L, Wright PF, Katz JM, Dally L, Rahman M, Isakova-Sivak I, Ilyushina NA, Matyushenko V, Fry AM, Lindstrom SE, Bresee JS, Brooks WA, Neuzil KM.

Clin Infect Dis. 2019 Aug 16;69(5):777-785. doi: 10.1093/cid/ciy1003.

4.

The use of plant lectins to regulate H1N1 influenza A virus receptor binding activity.

Lee N, Khalenkov AM, Lugovtsev VY, Ireland DD, Samsonova AP, Bovin NV, Donnelly RP, Ilyushina NA.

PLoS One. 2018 Apr 9;13(4):e0195525. doi: 10.1371/journal.pone.0195525. eCollection 2018.

5.

Influenza virus NS1 protein mutations at position 171 impact innate interferon responses by respiratory epithelial cells.

Plant EP, Ilyushina NA, Sheikh F, Donnelly RP, Ye Z.

Virus Res. 2017 Aug 15;240:81-86. doi: 10.1016/j.virusres.2017.07.021. Epub 2017 Jul 27.

6.

Generation and characterization of interferon-lambda 1-resistant H1N1 influenza A viruses.

Ilyushina NA, Lugovtsev VY, Samsonova AP, Sheikh FG, Bovin NV, Donnelly RP.

PLoS One. 2017 Jul 27;12(7):e0181999. doi: 10.1371/journal.pone.0181999. eCollection 2017.

7.

Impact of Influenza A Virus Infection on the Proteomes of Human Bronchoepithelial Cells from Different Donors.

Mindaye ST, Ilyushina NA, Fantoni G, Alterman MA, Donnelly RP, Eichelberger MC.

J Proteome Res. 2017 Sep 1;16(9):3287-3297. doi: 10.1021/acs.jproteome.7b00286. Epub 2017 Aug 16.

8.

Amino Acids in Hemagglutinin Antigenic Site B Determine Antigenic and Receptor Binding Differences between A(H3N2)v and Ancestral Seasonal H3N2 Influenza Viruses.

Wang X, Ilyushina NA, Lugovtsev VY, Bovin NV, Couzens LK, Gao J, Donnelly RP, Eichelberger MC, Wan H.

J Virol. 2017 Jan 3;91(2). pii: e01512-16. doi: 10.1128/JVI.01512-16. Print 2017 Jan 15.

9.

Effects of hemagglutinin amino acid substitutions in H9 influenza A virus escape mutants.

Rudneva IA, Timofeeva TA, Ignatieva AV, Shilov AA, Ilyushina NA.

Arch Virol. 2016 Dec;161(12):3515-3520. Epub 2016 Sep 1.

PMID:
27586413
10.

Correlates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza Vaccine.

Wright PF, Hoen AG, Ilyushina NA, Brown EP, Ackerman ME, Wieland-Alter W, Connor RI, Jegaskanda S, Rosenberg-Hasson Y, Haynes BC, Luke CJ, Subbarao K, Treanor JJ.

Open Forum Infect Dis. 2016 May 23;3(2):ofw108. doi: 10.1093/ofid/ofw108. eCollection 2016 Apr.

11.

In vitro modeling of the interaction between human epithelial cells and lymphocytes upon influenza infection.

Ilyushina NA, Wright PF.

Influenza Other Respir Viruses. 2016 Sep;10(5):438-42. doi: 10.1111/irv.12394. Epub 2016 May 17.

12.

Pleiotropic effects of amino acid substitutions in H5 hemagglutinin of influenza A escape mutants.

Kaverin NV, Rudneva IA, Timofeeva TA, Ignatieva AV, Shilov AA, Bovin NV, Ilyushina NA.

Virus Res. 2015 Dec 2;210:81-9. doi: 10.1016/j.virusres.2015.07.016. Epub 2015 Jul 26.

PMID:
26220479
13.

[Effect of amino acid substitutions in small subunit of avian H5N2 influenza virus hemagglutinin on selection of the mutants resistant to neutralizing monoclonal antibodies].

Ignatieva AV, Timofeeva TA, Rudneva IA, Shilov AA, Masalova OV, Klimova RR, Kushch AA, Ilyushina NA, Kaverin NV.

Mol Biol (Mosk). 2015 Mar-Apr;49(2):342-50. Russian.

14.

In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate.

Ilyushina NA, Donnelly RP.

Antiviral Res. 2014 Nov;111:112-20. doi: 10.1016/j.antiviral.2014.09.008. Epub 2014 Sep 20.

PMID:
25245230
15.

Live attenuated and inactivated influenza vaccines in children.

Ilyushina NA, Haynes BC, Hoen AG, Khalenkov AM, Housman ML, Brown EP, Ackerman ME, Treanor JJ, Luke CJ, Subbarao K, Wright PF.

J Infect Dis. 2015 Feb 1;211(3):352-60. doi: 10.1093/infdis/jiu458. Epub 2014 Aug 26.

16.

Labeling of influenza viruses with synthetic fluorescent and biotin-labeled lipids.

Ilyushina NA, Chernyy ES, Korchagina EY, Gambaryan AS, Henry SM, Bovin NV.

Virol Sin. 2014 Aug;29(4):199-210. doi: 10.1007/s12250-014-3475-1. Epub 2014 Jul 31.

PMID:
25160755
17.

Intestinal immunity is a determinant of clearance of poliovirus after oral vaccination.

Wright PF, Wieland-Alter W, Ilyushina NA, Hoen AG, Arita M, Boesch AW, Ackerman ME, van der Avoort H, Oberste MS, Pallansch MA, Burton AH, Jaffar MA, Sutter RW.

J Infect Dis. 2014 May 15;209(10):1628-34. doi: 10.1093/infdis/jit671. Epub 2014 Jan 23.

PMID:
24459191
18.

Pleiotropic effects of hemagglutinin amino acid substitutions of H5 influenza escape mutants.

Rudneva IA, Timofeeva TA, Ignatieva AV, Shilov AA, Krylov PS, Ilyushina NA, Kaverin NV.

Virology. 2013 Dec;447(1-2):233-9. doi: 10.1016/j.virol.2013.09.013. Epub 2013 Oct 4.

19.

B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination.

Sangster MY, Baer J, Santiago FW, Fitzgerald T, Ilyushina NA, Sundararajan A, Henn AD, Krammer F, Yang H, Luke CJ, Zand MS, Wright PF, Treanor JJ, Topham DJ, Subbarao K.

Clin Vaccine Immunol. 2013 Jun;20(6):867-76. doi: 10.1128/CVI.00735-12. Epub 2013 Apr 10.

20.

Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium.

Ilyushina NA, Ikizler MR, Kawaoka Y, Rudenko LG, Treanor JJ, Subbarao K, Wright PF.

J Virol. 2012 Nov;86(21):11725-34. doi: 10.1128/JVI.01477-12. Epub 2012 Aug 22.

21.

Both influenza hemagglutinin and polymerase acidic genes are important for delayed pandemic 2009 H1N1 virus clearance in the ferret model.

Ducatez MF, Ilyushina NA, Fabrizio TP, Rehg JE, Bovin NV, Webster RG, Webby RJ.

Virology. 2012 Oct 25;432(2):389-93. doi: 10.1016/j.virol.2012.06.018. Epub 2012 Jul 17.

22.

Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium.

Ilyushina NA, Bovin NV, Webster RG.

J Virol. 2012 May;86(9):4724-33. doi: 10.1128/JVI.06774-11. Epub 2012 Feb 29.

23.

Interactions of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.

Govorkova EA, Ilyushina NA, Marathe BM, McClaren JL, Webster RG.

Influenza Other Respir Viruses. 2011 May;5 Suppl 1:90-3. No abstract available.

PMID:
21751467
24.

A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.

Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS.

Antiviral Res. 2011 Apr;90(1):17-21. doi: 10.1016/j.antiviral.2011.02.001. Epub 2011 Feb 21.

PMID:
21316393
25.

Influenza A virus-induced early activation of ERK and PI3K mediates V-ATPase-dependent intracellular pH change required for fusion.

Marjuki H, Gornitzky A, Marathe BM, Ilyushina NA, Aldridge JR, Desai G, Webby RJ, Webster RG.

Cell Microbiol. 2011 Apr;13(4):587-601. doi: 10.1111/j.1462-5822.2010.01556.x. Epub 2010 Dec 29.

26.

Does pandemic A/H1N1 virus have the potential to become more pathogenic?

Ilyushina NA, Ducatez MF, Rehg JE, Marathe BM, Marjuki H, Bovin NV, Webster RG, Webby RJ.

MBio. 2010 Nov 16;1(5). pii: e00249-10. doi: 10.1128/mBio.00249-10.

27.

Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer.

Carr S, Ilyushina NA, Franks J, Adderson EE, Caniza M, Govorkova EA, Webster RG.

Pediatr Infect Dis J. 2011 Apr;30(4):284-8. doi: 10.1097/INF.0b013e3181ff863b.

28.

Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries.

Kashyap AK, Steel J, Rubrum A, Estelles A, Briante R, Ilyushina NA, Xu L, Swale RE, Faynboym AM, Foreman PK, Horowitz M, Horowitz L, Webby R, Palese P, Lerner RA, Bhatt RR.

PLoS Pathog. 2010 Jul 8;6(7):e1000990. doi: 10.1371/journal.ppat.1000990.

29.

Adaptation of pandemic H1N1 influenza viruses in mice.

Ilyushina NA, Khalenkov AM, Seiler JP, Forrest HL, Bovin NV, Marjuki H, Barman S, Webster RG, Webby RJ.

J Virol. 2010 Sep;84(17):8607-16. doi: 10.1128/JVI.00159-10. Epub 2010 Jun 30.

30.

Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.

Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA.

PLoS Pathog. 2010 May 27;6(5):e1000933. doi: 10.1371/journal.ppat.1000933.

31.

Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.

Govorkova EA, Ilyushina NA, Marathe BM, McClaren JL, Webster RG.

J Virol. 2010 Aug;84(16):8042-50. doi: 10.1128/JVI.00689-10. Epub 2010 Jun 2.

32.

Extensive mammalian ancestry of pandemic (H1N1) 2009 virus.

Ilyushina NA, Kim JK, Negovetich NJ, Choi YK, Lang V, Bovin NV, Forrest HL, Song MS, Pascua PN, Kim CJ, Webster RG, Webby RJ.

Emerg Infect Dis. 2010 Feb;16(2):314-7. doi: 10.3201/eid1602.091141.

33.

Readaptation of a low-virulence influenza H9 escape mutant in mice: the role of changes in hemagglutinin as revealed by site-specific mutagenesis.

Ilyushina NA, Rudneva IA, Khalenkov AM, Timofeeva TA, Krylov PS, Webster RG, Kaverin NV.

Arch Virol. 2010;155(1):107-10. doi: 10.1007/s00705-009-0535-1. Epub 2009 Nov 28.

34.

Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.

Govorkova EA, Ilyushina NA, McClaren JL, Naipospos TS, Douangngeun B, Webster RG.

Antimicrob Agents Chemother. 2009 Jul;53(7):3088-96. doi: 10.1128/AAC.01667-08. Epub 2009 Apr 6.

35.

Changes in H5N1 influenza virus hemagglutinin receptor binding domain affect systemic spread.

Yen HL, Aldridge JR, Boon AC, Ilyushina NA, Salomon R, Hulse-Post DJ, Marjuki H, Franks J, Boltz DA, Bush D, Lipatov AS, Webby RJ, Rehg JE, Webster RG.

Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):286-91. doi: 10.1073/pnas.0811052106. Epub 2008 Dec 30.

36.

Post-reassortment amino acid change in the hemagglutinin of a human-avian influenza H5N1 reassortant virus alters its antigenic specificity.

Rudneva IA, Timofeeva TA, Ilyushina NA, Varich NL, Kochergin-Nikitsky KS, Kaverin NV.

Acta Virol. 2008;52(3):181-4.

PMID:
18999893
37.

Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.

Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA.

Antimicrob Agents Chemother. 2008 Nov;52(11):3889-97. doi: 10.1128/AAC.01579-07. Epub 2008 Aug 25.

38.

Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.

Boltz DA, Ilyushina NA, Arnold CS, Babu YS, Webster RG, Govorkova EA.

Antiviral Res. 2008 Nov;80(2):150-7. doi: 10.1016/j.antiviral.2008.05.012. Epub 2008 Jun 23.

39.

Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.

Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG.

PLoS Pathog. 2008 Apr 11;4(4):e1000043. doi: 10.1371/journal.ppat.1000043.

40.

Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.

Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA.

J Virol. 2007 Nov;81(22):12418-26. Epub 2007 Sep 12.

41.

Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.

Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA.

Antivir Ther. 2007;12(3):363-70.

PMID:
17591026
42.

Inefficient transmission of H5N1 influenza viruses in a ferret contact model.

Yen HL, Lipatov AS, Ilyushina NA, Govorkova EA, Franks J, Yilmaz N, Douglas A, Hay A, Krauss S, Rehg JE, Hoffmann E, Webster RG.

J Virol. 2007 Jul;81(13):6890-8. Epub 2007 Apr 25.

43.

Contribution of H7 haemagglutinin to amantadine resistance and infectivity of influenza virus.

Ilyushina NA, Govorkova EA, Russell CJ, Hoffmann E, Webster RG.

J Gen Virol. 2007 Apr;88(Pt 4):1266-74.

PMID:
17374771
44.

Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.

Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG.

Antimicrob Agents Chemother. 2007 Apr;51(4):1414-24. Epub 2007 Feb 12.

45.

Effect of gene constellation and postreassortment amino acid change on the phenotypic features of H5 influenza virus reassortants.

Rudneva IA, Timofeeva TA, Shilov AA, Kochergin-Nikitsky KS, Varich NL, Ilyushina NA, Gambaryan AS, Krylov PS, Kaverin NV.

Arch Virol. 2007;152(6):1139-45. Epub 2007 Feb 9.

PMID:
17294090
46.

The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04.

Salomon R, Franks J, Govorkova EA, Ilyushina NA, Yen HL, Hulse-Post DJ, Humberd J, Trichet M, Rehg JE, Webby RJ, Webster RG, Hoffmann E.

J Exp Med. 2006 Mar 20;203(3):689-97. Epub 2006 Mar 13.

47.

Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants.

Ilyushina NA, Bovin NV, Webster RG, Govorkova EA.

Antiviral Res. 2006 Jul;70(3):121-31. Epub 2006 Feb 21.

PMID:
16516984
48.

Restoration of virulence of escape mutants of H5 and H9 influenza viruses by their readaptation to mice.

Rudneva IA, Ilyushina NA, Timofeeva TA, Webster RG, Kaverin NV.

J Gen Virol. 2005 Oct;86(Pt 10):2831-8.

PMID:
16186239
49.
50.

Postreassortment changes in a model system: HA-NA adjustment in an H3N2 avian-human reassortant influenza virus.

Ilyushina NA, Rudneva IA, Shilov AA, Klenk HD, Kaverin NV.

Arch Virol. 2005 Jul;150(7):1327-38. Epub 2005 Mar 24.

PMID:
15789269

Supplemental Content

Loading ...
Support Center